|
1.
|
|
12 p, 801.4 KB |
The Secondary Myelodysplastic Neoplasms (MDS) Jigsaw
/
Calvete, Oriol (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Mestre, Julia (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Jerez, Andrés (Vall d'Hebron Institut d'Oncologia) ;
Sole, F (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras)
There is a great deal of controversy in the hematologic community regarding the classification of secondary myelodysplastic neoplasms (MDSs). Current classifications are based on the presence of genetic predisposition and MDS post-cytotoxic therapy (MDS-pCT) etiologies. [...]
2023 -  10.3390/cancers15051483
Cancers, Vol. 15 Núm. 5 (march 2023) , p. 1483
|
|
|
2.
|
|
|
3.
|
|
9 p, 1.0 MB |
Cytotoxic NK cells phenotype and activated lymphocytes are the main characteristics of patients with alcohol-associated liver disease
/
Zurera Egea, Coral (Universitat Autònoma de Barcelona. Departament de Biologia Cel·lular, de Fisiologia i d'Immunologia) ;
Teniente Serra, Aina (Universitat Autònoma de Barcelona. Departament de Biologia Cel·lular, de Fisiologia i d'Immunologia) ;
Fuster, Daniel (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Martínez Cáceres, Eva María (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Muga, Roberto (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Zuluaga Blanco, Yenny Paola (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Universitat Autònoma de Barcelona
T cells, natural killer (NK) and NKT cells have opposing actions in the development of alcohol-associated liver fibrosis. We aimed to evaluate the phenotype of NK cells, NKT cells and activated T cells in patients with alcohol use disorder (AUD) according to the presence of advanced liver fibrosis (ALF). [...]
2023 - 10.1007/s10238-023-01121-1
Clinical and Experimental Medicine, Vol. 23, Num. 7 (november 2023) , p. 3539-3547
|
|
|
4.
|
|
|
5.
|
|
14 p, 3.5 MB |
Time-Prolonged Release of Tumor-Targeted Protein-MMAE Nanoconjugates from Implantable Hybrid Materials
/
Serna, Naroa (Universitat Autònoma de Barcelona. Institut de Biotecnologia i de Biomedicina "Vicent Villar Palasí") ;
Falgàs, Aïda (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
García-León, Annabel (Institut d'Investigació Biomèdica Sant Pau) ;
Unzueta Elorza, Ugutz (Universitat Autònoma de Barcelona. Departament de Genètica i de Microbiologia) ;
Núñez, Yáiza (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Sánchez Chardi, Alejandro (Universitat Autònoma de Barcelona. Servei de Microscòpia) ;
Martínez-Torró, Carlos (Centro de Investigación Biomédica en Red de Bioingeniería, Biomateriales y Nanomedicina) ;
Mangues, Ramon 1957- (Institut d'Investigació Biomèdica Sant Pau) ;
Vázquez Gómez, Esther (Universitat Autònoma de Barcelona. Institut de Biotecnologia i de Biomedicina "Vicent Villar Palasí") ;
Casanova Rigat, Isolda (Institut d'Investigació Biomèdica Sant Pau) ;
Villaverde Corrales, Antonio (Universitat Autònoma de Barcelona. Institut de Biotecnologia i de Biomedicina "Vicent Villar Palasí")
The sustained release of small, tumor-targeted cytotoxic drugs is an unmet need in cancer therapies, which usually rely on punctual administration regimens of non-targeted drugs. Here, we have developed a novel concept of protein-drug nanoconjugates, which are packaged as slow-releasing chemically hybrid depots and sustain a prolonged secretion of the therapeutic agent. [...]
2022 - 10.3390/pharmaceutics14010192
Pharmaceutics, Vol. 14 (january 2022)
|
|
|
6.
|
|
43 p, 2.2 MB |
Immune-Checkpoint Inhibitors in B-Cell Lymphoma
/
Armengol, Marc Antoni (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Profitós-Pelejà, Núria (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Ribeiro, Marcelo L. (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Roué, Gaël (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Santos, Juliana (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Fernández-Serrano, Miranda (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras)
For years, immunotherapy has been considered a viable and attractive treatment option for patients with cancer. Among the immunotherapy arsenal, the targeting of intratumoral immune cells by immune-checkpoint inhibitory agents has recently revolutionised the treatment of several subtypes of tumours. [...]
2021 - 10.3390/cancers13020214
Cancers, Vol. 13 Núm. 214 (2021) , p. 43
|
|
|
7.
|
|
14 p, 3.2 MB |
Mutations in Hepatitis D Virus Allow It to Escape Detection by CD8 + T Cells and Evolve at the Population Level
/
Karimzadeh, Hadi (Department of Internal Medicine II, University Hospital Munich-Grosshadern, Munich, Germany) ;
Kiraithe, Muthamia M. (Department of Medicine II, University Hospital Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany) ;
Oberhardt, Valerie (Faculty of Biology, University of Freiburg, Freiburg, Germany) ;
Salimi Alizei, Elahe (Faculty of Chemistry and Pharmacy, University of Freiburg, Freiburg, Germany) ;
Bockmann, Jan (German Center for Infection Research (DZIF), Sites Hamburg-Lübeck-Borstel-Riems, Hannover-Braunschweig and Munich, Germany) ;
Schulze zur Wiesch, Julian (German Center for Infection Research (DZIF), Sites Hamburg-Lübeck-Borstel-Riems, Hannover-Braunschweig and Munich, Germany) ;
Budeus, Bettina (Department of Bioinformatics, University of Duisburg-Essen, Essen, Germany) ;
Hoffmann, Daniel (Department of Bioinformatics, University of Duisburg-Essen, Essen, Germany) ;
Wedemeyer, Heiner (University Hospital Essen (Alemanya)) ;
Cornberg, Markus (Hannover Medical School. Department of Gastroenterology, Hepatology and Endocrinology) ;
Krawczyk, Adalbert (Department of Infectious Diseases, University Hospital of Essen, University of Duisburg-Essen, Essen, Germany) ;
Rashidi-Alavijeh, Jassin (University Hospital Essen (Alemanya)) ;
Rodríguez Frías, Francisco (Hospital Universitari Vall d'Hebron) ;
Casillas, Rosario (Hospital Universitari Vall d'Hebron) ;
Buti, Maria (Hospital Universitari Vall d'Hebron) ;
Smedile, Antonina (Department of Medical Sciences, University of Turin, Turin, Italy) ;
Alavian, Seyed Moayed (Baqiyatallah Research Center for Gastroenterology and Liver Diseases, Baqiyatallah University of Medical Sciences, Tehran, Iran) ;
Heinold, Andreas (University Hospital Essen (Alemanya)) ;
Emmerich, Florian (Institute for Transfusion Medicine and Gene Therapy, University Hospital Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany) ;
Panning, Marcus (Institute of Virology, University Hospital Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany) ;
Gostick, Emma (Division of Infection and Immunity, Cardiff University School of Medicine, Cardiff, United Kingdom) ;
Price, David A. (Division of Infection and Immunity, Cardiff University School of Medicine, Cardiff, United Kingdom) ;
Timm, Jörg (Institute of Virology, Heinrich-Heine-University, University Hospital, Duesseldorf, Germany) ;
Hofmann, Maike (Department of Medicine II, University Hospital Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany) ;
Raziorrouh, Bijan (Department of Internal Medicine II, University Hospital Munich-Grosshadern, Munich, Germany) ;
Thimme, Robert (Department of Medicine II, University Hospital Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany) ;
Protzer, Ulrike (German Center for Infection Research (DZIF), Sites Hamburg-Lübeck-Borstel-Riems, Hannover-Braunschweig and Munich, Germany) ;
Roggendorf, Michael (German Center for Infection Research (DZIF), Sites Hamburg-Lübeck-Borstel-Riems, Hannover-Braunschweig and Munich, Germany) ;
Neumann-Haefelin, Christoph (Department of Medicine II, University Hospital Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany) ;
Universitat Autònoma de Barcelona
Hepatitis D virus (HDV) superinfection in patients with hepatitis B virus (HBV) is associated with rapid progression to liver cirrhosis and hepatocellular carcinoma. Treatment options are limited, and no vaccine is available. [...]
2019 - 10.1053/j.gastro.2019.02.003
Gastroenterology, Vol. 156 (may 2019) , p. 1820-1833
|
|
|
8.
|
|
0 p, 5.4 MB |
Antigen production after latency reversal and expression of inhibitory receptors in CD8+ T cells limit the killing of HIV-1 reactivated cells
/
Ruiz, A. (Institut Germans Trias i Pujol. Institut de Recerca de la Sida IrsiCaixa) ;
Blanch-Lombarte, Oscar (Institut Germans Trias i Pujol. Institut de Recerca de la Sida IrsiCaixa) ;
Jiménez-Moyano, Esther (Institut Germans Trias i Pujol. Institut de Recerca de la Sida IrsiCaixa) ;
Ouchi, Dan (Institut Germans Trias i Pujol. Institut de Recerca de la Sida IrsiCaixa) ;
Mothe, Beatriz. (Institut Germans Trias i Pujol. Institut de Recerca de la Sida IrsiCaixa) ;
Peña, R. (Institut Germans Trias i Pujol. Institut de Recerca de la Sida IrsiCaixa) ;
Gálvez, Cristina (Institut Germans Trias i Pujol. Institut de Recerca de la Sida IrsiCaixa) ;
Genescà Ferrer, Meritxell. (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Martínez Picado, Francisco Javier (Institut Germans Trias i Pujol. Institut de Recerca de la Sida IrsiCaixa) ;
Goulder, P. (Department of Paediatrics. University of Oxford) ;
Barnard, R. (Department of Infectious Disease. Merck and Co. Inc.) ;
Howell, B. (Department of Infectious Disease. Merck and Co. Inc.) ;
Pérez-Álvarez, Núria (Institut Germans Trias i Pujol. Institut de Recerca de la Sida IrsiCaixa) ;
Prado, Julia G.. (Institut Germans Trias i Pujol. Institut de Recerca de la Sida IrsiCaixa) ;
Universitat Autònoma de Barcelona
The so-called shock and kill therapies aim to combine HIV-1 reactivation by latency-reversing agents (LRA) with immune clearance to purge the HIV-1 reservoir. The clinical use of LRA has demonstrated detectable perturbations in the HIV-1 reservoir without measurable reductions to date. [...]
2019 - 10.3389/fimmu.2018.03162
Frontiers in immunology, Vol. 10 Núm. JAN (2019) , p. 3162
|
|
|
9.
|
|
10 p, 868.0 KB |
Defining the HLA class I-associated viral antigen repertoire from HIV-1-infected human cells
/
Ternette, Nicola (University of Oxford. The Jenner Institute, Nuffield Department of Medicine) ;
Yang, Hongbing (University of Oxford. Nuffield Department of Medicine) ;
Partridge, Thomas (University of Oxford. Nuffield Department of Medicine) ;
Llano Montero, Anuska (Institut Germans Trias i Pujol. Institut de Recerca de la Sida IrsiCaixa) ;
Cedeño, Samandhy (Institut Germans Trias i Pujol. Institut de Recerca de la Sida IrsiCaixa) ;
Fischer, Roman (University of Oxford. Nuffield Department of Medicine) ;
Charles, Philip D. (University of Oxford. Nuffield Department of Medicine) ;
Dudek, Nadine L. (Monash University. Department of Biochemistry and Molecular Biology) ;
Mothe, Beatriz (Institut Germans Trias i Pujol. Institut de Recerca de la Sida IrsiCaixa) ;
Crespo Casal, Manuel (Hospital Universitari Vall d'Hebron) ;
Fischer, William M. (Los Alamos National Laboratory. Group T-6, Theoretical Biology) ;
Korber, Bette T. M. (Los Alamos National Laboratory. Group T-6, Theoretical Biology) ;
Nielsen, Morten (Technical University of Denmark. Center for Biological Sequence Analysis) ;
Borrow, Persephone (University of Oxford. Nuffield Department of Medicine) ;
Purcell, Anthony W. (Monash University. Department of Biochemistry and Molecular Biology) ;
Brander, Christian (Institució Catalana de Recerca i Estudis Avançats) ;
Dorrell, Lucy (University of Oxford. The Jenner Institute, Nuffield Department of Medicine) ;
Kessler, Benedikt M. (University of Oxford. Nuffield Department of Medicine) ;
Hanke, Tomáš (University of Oxford. The Jenner Institute, Nuffield Department of Medicine) ;
Universitat Autònoma de Barcelona
Recognition and eradication of infected cells by cytotoxic T lymphocytes is a key defense mechanism against intracellular pathogens. High-throughput definition of HLA class I-associated immunopeptidomes by mass spectrometry is an increasingly important analytical tool to advance our understanding of the induction of T-cell responses against pathogens such as HIV-1. [...]
2015 - 10.1002/eji.201545890
European Journal of Immunology, Vol. 46 (november 2015) , p. 60-69
|
|
|
10.
|
|
22 p, 1.1 MB |
Type 1 diabetes prevention in NOD mice by targeting DPPIV/CD26 is associated with changes in CD8+T effector memory subset
/
Alonso Pedrol, Núria (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Julián, María Teresa (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Carrascal, Jorge (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Colobrán Oriol, Roger (Universitat Autònoma de Barcelona. Departament de Biologia Cel·lular, de Fisiologia i d'Immunologia) ;
Pujol-Autonell, Irma (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Rodriguez Fernandez, Silvia (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Teniente Serra, Aina (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Fernández Sanmartin, Marco Antonio (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Miñarro Alonso, Antoni (Universitat de Barcelona. Departament d'Estadística) ;
Ruiz de Villa, María del Carmen (Universitat de Barcelona. Departament d'Estadística) ;
Vives Pi, Marta (Universitat Autònoma de Barcelona. Departament de Biologia Cel·lular, de Fisiologia i d'Immunologia) ;
Puig Domingo, Manuel (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Universitat Autònoma de Barcelona.
Departament de Medicina
CD26 is a T cell activation marker consisting in a type II transmembrane glycoprotein with dipeptidyl peptidase IV (DPPIV) activity in its extracellular domain. It has been described that DPPIV inhibition delays the onset of type 1 diabetes and reverses the disease in non-obese diabetic (NOD) mice. [...]
2015 - 10.1371/journal.pone.0142186
PloS one, Vol. 10, Issue 11 (Novembre 2015) , p. e0142186
|
|
visitant ::
identificació
alerta personal via correu electrònic o subscribiu-vos al 
canal RSS.
